What the Research Shows About BPC-157 and Cancer The scientific literature on BPC-157 contains no studies demonstrating cancer promotion
( i ) Fasting plasma GIP (n = 5 per group), ( j ) total GLP-1 (CON n = 9, Gipr AP-KO n = 8), ( k ) insulin (CON n = 5, GIPR AP-KO n = 4), (l) food intake post IPGTT (CON n = 6, Gipr AP-KO n = 6), ( m ) ad lib fed blood glucose (CON n = 6, Gipr AP-KO n = 6), (n) RER (time x group F(24, 168) = 1.739 p = 0.023), ( o ) energy expenditure (with ANCOVA using BW as covariate), ( p ) ambulatory activity (x beam breaks)
Using both can tackle multiple issues at once, leading to better results
The Phase 2 SHAPE trial (NCT04831281) in Parkinsons disease dementia and dementia with Lewy bodies failed its primary endpoint in December 2023